Table 2.
Current risk-adapted studies using interim PET in Hodgkin's lymphoma.
| Study | Group | Projected accrual | Timing of PET | Treatment |
|---|---|---|---|---|
| Limited disease: | ||||
| RAPID trial [47] | UK NCRI | 1600 | After ABVD × 3 | PET−, randomize to RT versus no further therapy |
| PET+, further ABVD + RT | ||||
| HD16 [48] | GHSG | 1100 | After ABVD × 2 | Standard arm: RT regardless of PET |
| Experimental: PET−, no further therapy | ||||
| Experimental: PET+, RT | ||||
| H10 [49] | EORTC, GELA, IIL | 1600 | After ABVD × 2 | Standard arm: complete ABVD + RT regardless of PET |
| Experimental: PET−, complete ABVD (no RT) | ||||
| Experimental: PET+, BEACOPPesc then RT | ||||
|
| ||||
| Advanced disease: | ||||
| HD18 [50] | GHSG | 1500 | After BEACOPPesc × 2 | PET−, randomize to 2 versus 6 more cycles (no RT) |
| PET+, randomize to BEACOPPesc with versus without rituximaba | ||||
| HD0607 [53] | GITIL | 450 | After ABVD × 2 | PET−, complete ABVD; if still PET–, randomize to RT versus no RT |
| PET+, randomize to BEACOPPesc with versus without rituximabb | ||||
| RATHL [51] | UK NCRI | 1200 | After ABVD × 2 | PET−, randomize to ABVD versus AVD (no RT) |
| PET+, BEACOPP-14 or BEACOPPesc | ||||
| HD0801 [52] | IIL | 300 | After ABVD × 2 | PET−, complete ABVD; if still PET–, randomize to RT versus no RT |
| PET+, high-dose therapy with autologous BMT | ||||
| S0816 [54] | SWOG intergroup | 230 | After ABVD × 2 | PET−, further ABVD |
| PET+, BEACOPPescc | ||||
ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; BMT: blood or marrow transplantation; EORTC: European Organization for Research and Treatment of Cancer; esc, escalated; GELA: Groupe d'Étude des Lymphomes de l'Adulte; GHSG: German Hodgkin Study Group; GITIL: Gruppo Italiano Terapie Innovative Nei Linfomi; IIL: Intergruppo Italiano Linfomi; NCRI: National Cancer Research Institute; RATHL: response-adapted therapy in Hodgkin lymphoma; RT: radiation therapy; SWOG: Southwest Oncology Group.
aRT restricted to residual ≥2.5 cm, PET+ sites on end-of-chemotherapy imaging.
bIf PET− after 4 cycles of BEACOPPesc ± rituximab, changed to standard BEACOPP ± rituximab.
cStandard BEACOPP if human immunodeficiency virus positive.